Pharmaceutical Cold Chain Software POC Purgatory: Why Technology Evaluations Keep Failing

Over the past month, I have had three separate conversations with pharmaceutical and biotech companies preparing to run proofs of concept for pharmaceutical cold chain software.

That alone is not particularly unusual.

What was unusual was the reason.

It was not:

"We have never implemented this type of technology before, and we need to determine whether it can create value."

It was closer to:

"We were a bit hasty with our last selection. We bought what was on the slide. It turns out the product does not actually work that way."

Or:

"The integrations have proven to be much more difficult than we were led to believe."

Or my personal favorite:

"They didn't pass our GxP validation."

Ouch.

These companies had already completed procurement exercises, compared vendors, reviewed demonstrations, evaluated security documentation, negotiated contracts and selected established providers of pharmaceutical cold chain software.

Then reality showed up.

Now Pharma has to pay for that failed decision all over again.

Not necessarily through another software contract, but through the additional burden placed on the next evaluation.

The next project team has to prove more.

Quality needs to get involved earlier.

IT needs to dig deeper into integrations.

CSV needs more documentation.

Procurement needs more references.

Operations needs to test more edge cases.

Leadership needs greater confidence before approving another investment.

What should have been a focused technology evaluation becomes an organizational trust-rebuilding exercise.

The new team inherits skepticism it did not create.

The new initiative inherits delays caused by the last one.

And the business is forced to spend more time, more money and more internal political capital proving that it will not make the same mistake twice.

Welcome to POC purgatory.

Why Pharma Cold Chain Software RFPs No Longer Work

Historically, the enterprise technology sales process was relatively simple.

First, claw your way into an RFP.

Then demonstrate that your product can meet the requirements, prove the financial case and win the business.

Sometimes, a capability was so differentiated—or the value was so obvious—that the customer would move directly toward a contract without conducting a formal RFP.

But generally, the RFP served one of two primary purposes:

1. De-risk the technical capability. Can the vendor actually do what it says it can do?
2. Validate the value. Does the expected ROI resemble what was promised during the sales process?

The demonstration, written response, technical review, reference calls and implementation plan were supposed to create enough confidence to make a decision.

A POC might still be required for something highly novel, technically complex or operationally sensitive.

It was not supposed to become the default response to every pharmaceutical cold chain software evaluation because the previous selection failed to deliver.

That is where we are heading.

The POC is increasingly becoming less of an innovation exercise and more of a credibility audit.

Prove your integrations work.

Prove your product is validated.

Prove the AI is more than a chat window.

Prove your team can implement on the first try and in the designated time window.

Prove the feature shown in the demo is generally available and not being held together backstage with duct tape, professional services and an exhausted solutions engineer.

In other words:

Prove that we are buying the product—not the PowerPoint.

The Checkbox Problem in Pharmaceutical Cold Chain Software Evaluations

There are hard truths and painful lessons buried in this trend.

As they say, the devil is in the details.

Unfortunately, the way many RFPs are structured today is almost perfectly designed to avoid those details.

Does Vendor 1 offer a visibility control tower?

Yes.

So do Vendors 2 and 3.

Is Vendor 1 GxP-validated and SOC 2 compliant?

Yes.

The others checked those boxes too.

Does Vendor 1 offer AI functionality?

Of course.

Apparently, everybody does now.

Does the platform support integrations?

Yes. There is an API.

Fantastic. Case closed.

The problem is that the requirements are written at such a superficial level that every vendor can provide essentially the same answer.

"Yes."

Yet the actual differences do not emerge until after the selection has been made.

A ‘visibility control tower’ might mean a genuinely data-agnostic platform that unifies active IoT devices, passive loggers, carrier milestones, ELDs & trailer telematics, shipment documentation, product specifications, SOPs and quality information into one shipment record.

Or it might mean a dot on a map powered by one device manufacturer.

"GxP-validated" might mean a product was designed with native audit trails, electronic records, governed workflows and the documentation necessary to support the customer’s intended use.

Or it might mean the vendor once completed a validation-related project for somebody, somewhere.

"AI-enabled" might mean models grounded in the customer’s SOPs, Lane Risk Assessments, Distribution Risk Assessments, product profiles and actual shipment history, with recommendations traceable to evidence.

Or it might mean a generic language model married up to a dashboard.

You get the picture…

These are not minor distinctions.

They determine whether the implementation takes weeks or years.

They determine whether users adopt the product or return to spreadsheets.

They determine whether Quality approves the system or stops the deployment in its tracks.

And most importantly, they almost always determine whether the Pharma will invest in accruing tech debt versus actual value.

Why Pharma Is Right to Demand More From Cold Chain Software Vendors

Technology vendors love to complain about POCs… myself included!

They take too long.

They consume engineering resources.

They are sometimes poorly scoped.

They can turn into unpaid consulting engagements with no defined decision date.

All true.

But Pharma did not create this environment for fun.

The industry is reacting to years of vendors over-promising, under-scoping integrations, obscuring product limitations and selling future roadmap items as current functionality.

A failed technology selection is painful in any industry.

In Pharma, it can also create compliance exposure, delay product release, disrupt global distribution and consume months of work across Logistics, Quality, IT, Security, Validation and Procurement.

Replacing the product does not magically return that time.

The organization must unwind integrations, migrate data, revisit requirements, repeat validation activities and convince internal stakeholders that the next program will somehow be different.

That creates institutional scar tissue.

The POC becomes the response.

Unfortunately, Pharma then risks swinging too far in the opposite direction.

A badly designed POC does not necessarily uncover the truth either.

If it uses pristine sample data, avoids difficult edge cases and only tests the vendor’s strongest workflow, it is just an extended demonstration.

If there are no measurable objectives, success criteria or contractual path forward, it becomes an innovation science project.

If the POC lasts six months but the production rollout is expected to handle entirely different data, integrations, users and volumes, very little has been de-risked.

That is how companies end up in permanent POC purgatory: endlessly testing technologies without building enough confidence to deploy any of them.

How to Evaluate Pharmaceutical Cold Chain Software

A better evaluation begins by changing the questions.

Do not ask whether the platform has a visibility control tower.

Rather, ask the vendor:

• which data sources it can unify on a singular shipment record, or
• how many unilateral buffered device pings it can process at one time on a single shipment, or
• how it’s deploying an agentic workflow without a lane baseline

Do not ask whether the product supports integrations.

Rather, ask the vendor:

• for an integration playbook
• for consultative advice on an integration strategy
• sample integration documentation supporting all the various kinds of ‘supported integrations’

Do not ask whether the pharma cold chain software platform is GxP-validated.

Rather, ask the vendor:

• for their validation pack
• SDLC documentation
• audit certifications
• a reference customer that has already validated the solution

Not after selection. During the RFP.

Once again, you get the picture…

Most importantly, stop evaluating isolated features.

Cold chain operations are not meant to happen in silos.

They happen across a connected product transportation lifecycle.

A lane is qualified.

A shipment is created.

Transportation and condition data are generated.

Risk is monitored.

Exceptions are investigated.

Quality determines disposition.

The data is aggregated.

Improvements are systematically identified and implemented back into the re-qualification process.

What happened in the real world should then improve the next lane qualification, carrier selection, packaging choice, route decision and SOP.

If the pharmaceutical cold chain software cannot connect those steps, you are not buying an operating system.

You are buying another point solution that someone will eventually have to integrate with all the others.

How CONTXT Solves Pharmaceutical Cold Chain Operations

This lifecycle is exactly how we designed PAXAFE’s CONTXT Intelligence Platform.

Not as four unrelated products.

Not as a visibility portal with a handful of recently added AI features.

And not as another generic supply chain platform being forced into a regulated pharmaceutical environment.

CONTXT is logistics orchestration and quality compliance software built specifically to eliminate data silos & consolidate platforms, digitize & automate compliance workflows, and enable faster, better decisions.

It begins with Lane Qualification, where SOPs, Distribution Risk Assessments and Lane Risk Assessments are digitized, governed and tied directly to the lane and shipment records they are meant to control.

It moves into the Command Center, where active devices, passive loggers, carriers and enterprise systems are unified into a single shipment record. Exceptions are evaluated using product, packaging, route, timing and SOP context—not merely whether a device or carrier generated an alert.

It extends through Product Release, where device-agnostic temperature data, product profiles, time-out-of-range calculations, approval workflows and disposition evidence are assembled & dispositioned within a GxP-validated process and complete audit trail.

It culminates in Insights, where real-world performance is compared against what was planned. Root causes, patterns and prescriptive recommendations feed back into future qualification and operating decisions.

Athena AI® works across that lifecycle. Its purpose is not to sit beside the platform and summarize generic data. It is grounded in the customer’s SOPs, qualification records, shipment history, product information and cold chain context.

That distinction is important.

The real proof is not whether each module looks attractive in a demonstration.

The proof is whether the information moves through the lifecycle.

Can the qualified lane inform monitoring?

Can the SOP determine whether an exception requires intervention?

Can shipment and temperature records accelerate product release?

Can actual performance update the assumptions used to qualify the lane?

Can the platform explain why it made a recommendation and identify the evidence behind it?

That is what should be tested.

Run a Real Pharmaceutical Cold Chain Software POC

We do not believe a POC should last forever.

It should have a defined problem, a limited but meaningful scope, representative data, measurable success criteria and a clear decision at the end.

Start small.

But make it real.

Use your own data.

Include the ugly PDFs and the unstructured data.

Include the inconsistent carrier milestones.

Include the passive logger files from three different manufacturers.

Bring the shipment with multiple devices.

Bring in Quality.

Bring in CSV.

Ask the uncomfortable integration questions before the contract—not six months afterward.

Good vendors should welcome that level of scrutiny.

Because the details that expose an underbuilt product are often the same details that reveal a truly differentiated one.

Pharma does not need another perfect demonstration.

It needs evidence that the pharmaceutical cold chain software will work inside the imperfect, fragmented and highly regulated environment that actually exists.

The industry has bought enough slides.

It is time to show the work.